BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2004

View Archived Issues

Serostim reduces visceral adipose tissue in HARS study

Read More

JNJ-7777120, a potent histamine H4 receptor antagonist with antiinflammatory activity

Read More

BMS describes novel, potent motilin agonist for treatment of GI hypomotility disorders

Read More

Efficacy of Menocare in management of menopausal symptoms

Read More

Par and Advancis to develop pulsatile amoxicillin

Read More

NexMed plans Chinese FSAD phase III study for Femprox

Read More

CytoGenix DNA antibacterial compound shows preclinical promise for sepsis

Read More

Alagebrium chloride approved as generic name for ALT-711

Read More

EMEA accepts Exubera filing

Read More

KOS-862 studied in combination with Gemzar for advanced solid tumors

Read More

Actiza NDA accepted for filing

Read More

Positive phase II results for BAL-5788

Read More

Nippon Shinyaku and Seikagaku terminate NS-7201 license agreement

Read More

Antigen Express to develop diagnostic kit for early detection of type 1 diabetes

Read More

Intrathecal Naropin recommended for approval in Europe

Read More

LifeSci Channel broadcasts ADA's 51st Postgraduate Course

Read More

Therapeutic antibodies with reduced side effects presented by Isis Innovation

Read More

Two novel series of SERM and their use reported by Lilly

Read More

Euroceltique claims new VR1/mGluR antagonists in a recent patent

Read More

AstraZeneca team develops new CXCR2 modulators for asthma, rhinitis, COPD, etc.

Read More

Aventis patent covers novel MCH receptor modulators for obesity and other uses

Read More

New antibacterial quinolines prepared and tested at Aventis

Read More

Novel anti-HIV agents in early development at BMS

Read More

Two series of sodium channel blockers discovered by Euroceltique scientists

Read More

FDA approval for Taxus Express2 stent

Read More

Adventrx files IND for BlockAide/CR phase Ib/IIa trials

Read More

LymphoStat-B selected for CMA Pilot 2 program

Read More

Positive results for MMH Malarex in comparative study with Camoquine

Read More

Kucera discovers novel antiviral compounds with potential for SARS

Read More

A new clinical trial to assess the efficacy and safety of RotaTeq(TM) against rotavirus infection

Read More

Antiretroviral efficacy of atazanavir plus enfuvirtide in HIV infection

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing